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GUIDELINES
Atrial fibrillation: diagnosis and management—summary of NICE
guidance
Mark Perry, 1 Sophia Kemmis Betty, 1 Nicole Downes, 1 Neil Andrews, 2 Simon Mackenzie3, on behalf of
the Guideline Committee
What you need to know
• Bleeding risk assessment should be used to derive
accurate absolute risk scores that can support
discussion between clinician and patient about risk
modification and appropriate vigilance during
anticoagulation. It should not be used to set a
threshold for who should be offered anticoagulation
• The ORBIT bleeding prediction tool currently provides
the most accurate level of absolute bleeding risk
• Direct-acting oral anticoagulants (DOACs) should be
used in preference to warfarin for most patients; the
choice of DOAC depends on patient choice and
clinical indication
• Radiofrequency point-by-point ablation is the most
cost effective treatment for people who have not
responded to antiarrhythmic drugs, although laser
and cryoballoon ablation may be appropriate in some
patients
• Continue anticoagulation after ablation according to
risk tools
This article summarises the updated National
Institute for Health and Care Excellence (NICE)
guideline, Atrial fibrillation: diagnosis and
management,1 focusing on three areas where new
evidence has led to a change in recommendations:
bleeding risk prediction, anticoagulation, and
ablation. We explain the Guideline Committee’s
rationale for these recommendations and highlight
challenges to implementation.
Recommendations
NICE recommendations are based on systematic
reviews of best available evidence and explicit
consideration of cost effectiveness. When minimal
evidence is available, recommendations are based
on theGuidelineCommittee's experience andopinion
of what constitutes good practice. Evidence levels for
the recommendations reproduced here are given in
italics in square brackets.
Assessment of bleeding risks
For predicting the need for anticoagulation in people
diagnosed with atrial fibrillation, the CHA2DS2-VASc
score was retained as the recommended stroke risk
tool (fig 1) because it was the most accurate tool for
discriminating between those at risk of stroke and
those not at risk. In contrast, the choice of tool to
assess bleeding riskwas less based ondiscrimination
ability and more on the ability to provide an accurate
assessment of the absolute risk of bleeding for an
individual (box 1), and the Guideline Committee
recommends ORBIT for this purpose (box 2).
Box 1: Discrimination and calibration of prediction tools
Discrimination and calibration are both important
features in assessing prediction tool performance.
Discrimination
The “discrimination” ability of a prediction tool describes
how accurately the tool can categorise people into those
at higher and lower risk of an outcome (such as stroke)
• Accuracy of discrimination is measured by observing
‐ How many who later get the outcome were
correctly designated as higher risk, and
‐ How many who do not subsequently get the
outcome were correctly designated as lower risk.
• Discrimination alone is inadequate to assess a tool’s
overall predictive ability.
Calibration
The “calibration” ability of a tool describes the agreement
between predicted absolute risk and the true (observed)
risk in people discriminated into different risk groups.
Calibration therefore measures the accuracy of the
absolute risk estimates.
• High calibration indicates that the tool’s predicted
absolute risk is accurate, and is important when an
accurate absolute measure of risk is needed. For
example, high calibration is relevant when tools are
being used to facilitate discussion with the patient
about the need for risk modification and vigilance.
The committee agreed that, even if bleeding risk is
high, anticoagulation should still be considered for
people at risk of stroke. Therefore, a bleeding risk
tool should not normally be used to make decisions
about who should be anticoagulated. Instead, the
tool should be used to provide an accurate
assessment of absolute bleeding risk, which can
support discussion between patient and clinician,
facilitating optimal approaches to anticoagulation.
For example, accurate knowledge of bleeding risk
may increase compliancewith anticoagulationwhen
bleeding risks are low but promote appropriate
attention to risk modification during anticoagulation
when risk is high. Consequently, a bleeding risk tool’s
ability to accurately estimate absolute risk—its level
of calibration—is more useful than its discriminative
capacity.
The committee therefore focused on calibration data
for the tools with the most evidence: HAS-BLED,
ATRIA, and ORBIT. The calibration evidence clearly
suggested that ORBIT was more accurate than
HAS-BLED and ATRIA at predicting absolute risk of
major bleeding, both for people using vitamin K
antagonists and those using direct-acting oral
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anticoagulants. Importantly, ORBIT was better calibrated at all,
including higher, levels of major bleeding risk. ORBIT was also
better at predicting absolute risk of intracranial haemorrhage. All
three tools had similar discriminative ability, but ORBIT had a
slighter lower sensitivity for major bleeding than the others, and
better specificity. The committee concluded that the slight reduction
in ORBIT’s sensitivity would not be a particular drawback given
thatORBIT shouldnot beused to define a binary decision threshold.
Box 2: ORBIT bleeding prediction tool
The ORBIT bleeding prediction tool provides an absolute risk of bleeding,
which has been shown to calibrate well with observed incidence of
bleeding. An online version can be found at https://www.mdcalc.com/or-
bit-bleeding-risk-score-atrial-fibrillation.
ORBIT provides an absolute risk quantified by the number of bleeds per
100 patient years. This is based on each patient’s sex, haemoglobin (or
haematocrit) levels, age, bleeding history, glomerular filtration rate (GFR),
and treatment with antiplatelet agents (see table). The absolute risk is
calculated from the total score from the points allocated to each binary
response.
Possible responses (points allocated)Characteristic
FemaleMaleSex
Yes (2)No (0)Low haemoglobin or
haematocrit*
Yes (1)No (0)Age >74 years
Yes (2)No (0)Bleeding history†
Yes (1)No (0)GFR <60 mL/min/1.73 m2
Yes (1)No (0)Treatment with antiplatelet
agents
* For males, haemoglobin <13 mg/dL, haematocrit <40%. For females, haemoglobin <12 mg/dL
haematocrit <36%.
†Any history of gastrointestinal bleeding, intracranial bleeding, or haemorrhagic stroke.
Each ORBIT score is associated with a discrete absolute risk as shown
in the table below:
Absolute risk (No of bleeds/ 100 patient
years (95% CI))
ORBIT score
1.7 (1.2 to 2.4)0
2.3 (1.9 to 2.9)1
2.9 (2.3 to 3.5)2
4.7 (4.0 to 5.6)3
6.8 (5.8 to 8.1)4
9.0 (7.2 to 11.2)5
12.3 (9.0 to 16.7)6
14.9 (8.9 to 25.3)7
• Assess the risk of bleeding when:
‐ Considering starting anticoagulation in people with atrial
fibrillation and
‐ Reviewing people already taking anticoagulation.
Use the ORBIT bleeding risk score because evidence shows
that it has a higher accuracy in predicting absolute bleeding
risk than other bleeding risk tools. Accurate knowledge of
bleeding risk supports shared decision making and has
practical benefits; for example, increasing patient confidence
and willingness to accept treatment when risk is low and
prompting discussion of risk reduction when risk is high.
Although ORBIT is the best tool for this purpose, other
bleeding risk tools may need to be used until it is embedded
in clinical pathways and electronic systems. [New
guidance.Based on very low to low quality data]
• Offermonitoring and support tomodify risk factors for bleeding,
including:
‐ Uncontrolled hypertension (see NICE guideline Hypertension
in adults2)
‐ Poor control of international normalised ratio (INR) inpatients
taking vitamin K antagonists
‐ Concurrent medication, including antiplatelets, selective
serotonin reuptake inhibitors (SSRIs), and non-steroidal
anti-inflammatory drugs (NSAIDs)
‐ Harmful alcohol consumption (seeNICEguidelineAlcohol-use
disorders3)
‐ Reversible causes of anaemia.
[New guidance. Based on very low to low quality data]
Anticoagulation to prevent stroke
The committee recommends direct-acting oral anticoagulants
(DOACs) because evidence showed that they aremore effective than
warfarin in preventing harm in people at risk of stroke. There were
no studies directly comparing the different DOACs, but indirect
comparisons showed that different DOACs offer different benefits
depending on the outcome considered. When all these outcomes
were combined in the cost effectiveness analysis, apixaban was the
most clinically effective and cost effective anticoagulant, based on
UKdrug tariff prices at the time.However, theGuidelineCommittee
hadconcernsover the lackofhead-to-headcomparisons, differences
in the study populations, and uncertainties in the economic model,
and decided not to recommend one DOAC over the others. Instead
they emphasised that DOAC treatment should be tailored to the
person’s clinical needs and preferences, considering the different
risks and benefits of each. The committee agreed that, in the rare
circumstances that anticoagulation is not given to people at risk of
stroke because of very high bleeding risk, people should have
regular review and reconsideration for treatment.
• When deciding between anticoagulation treatment options:
‐ Discuss the risks and benefits of different drugs with the
person and follow the recommendations on shared decision
making in the NICE guideline Patient experience in adult NHS
services.4
‐ Follow the recommendations on patient involvement in
decisions about medicines in NICE guideline Medicines
adherence5 and patient decision aids in Medicines
optimisation.6
‐ Take into account any contraindications for each drug and
follow the guidance in the British National Formulary and the
Medicines and Healthcare products Regulatory Agency
(MHRA) advice Direct-acting oral anticoagulants (DOACS),7
in particular for advice on dosages in people with renal
impairment, reversal agents, and monitoring.
[New guidance.Based on the experience and opinion of the
Guideline Committee (GC)]
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• Offer anticoagulation with a direct-acting oral anticoagulant to
people with atrial fibrillation and a CHA2DS2-VASc score of 2 or
above, taking into account the risk of bleeding. Apixaban,
dabigatran, edoxaban, and rivaroxaban are all recommended
as options, when used in line with the criteria specified in the
relevantNICE technologyappraisal guidance (seeanticoagulation
treatment in the NICE PathwayAtrial fibrillation overview8). [New
guidance. Based on very low to moderate quality data]
• Consider anticoagulation with a direct-acting oral anticoagulant
for men with atrial fibrillation and a CHA2DS2-VASc score of 1,
taking into account the risk of bleeding. Apixaban, dabigatran,
edoxaban and rivaroxaban are all recommended as options,
when used in line with the criteria specified in the relevant NICE
technology appraisal guidance (see anticoagulation treatment
in the NICE Pathway Atrial fibrillation overview8). [Newguidance.
Based on very low to moderate quality data]
• If direct-acting oral anticoagulants are contraindicated, not
tolerated, or not suitable in people with atrial fibrillation, offer
a vitamin K antagonist. See the section on self monitoring and
selfmanagement of vitaminKantagonists. [Newguidance. Based
on the experience and opinion of the GC]
Left atrial ablation
No major changes were made to non-ablative treatment
recommendations, with rate control drugs recommended as the
first line approach, followed by antiarrhythmic drug treatment if
rate control drugs are unsuccessful. Ablation may be a treatment
option if antiarrhythmic drug treatment has not been successful or
is not tolerated (fig 2), and new evidence showed that the catheter
ablation techniques (radiofrequencypoint-by-point, radiofrequency
multi-electrode, laser, and cryoballoon) are the most clinically
effective ablation options. These techniques have similar efficacy
to each other, each generating a marked reduction in the rate of
atrial fibrillation recurrence compared with medical treatment,
while having a rate of serious adverse events similar to medical
treatment. Thoracoscopy and the hybrid techniques lead to even
lower atrial fibrillation recurrence, but they also lead tomore serious
adverse effects.
A new economic model developed for the guideline that used the
clinical evidence from people with paroxysmal atrial fibrillation
showed that radiofrequency point-by-point ablation was more cost
effective over a lifetime than antiarrhythmic drug treatment and
other ablation strategies in people for whom one or more
antiarrhythmic drug had failed.
Cryoballoon, radiofrequency multi-electrode, and laser ablation
were the second, third, and fourth most cost effective options
respectively. Despite further analysis to account for possible
inaccuracies in NHS reference costs, radiofrequency point-by-point
ablation remained the most cost effective option, and other catheter
ablation techniques are therefore unlikely to provide a cost effective
use of NHS resources. Based on the economic model results, the
committee agreed that radiofrequency point-by-point ablation
shouldbe considered inpeoplewith symptomatic paroxysmal atrial
fibrillation if drug treatment is unsuccessful, unsuitable, or not
tolerated.
Cryoballoon and laser ablation may sometimes be more suitable
for some patients because they may be carried out without general
anaesthesia, and cryoballoon ablation may be quicker, with same
day discharge more likely. There is also a risk of fluid overload from
saline irrigated radiofrequency ablation. The committee therefore
decided that either cryoballoonor laser ablation couldbe considered
if radiofrequency point-by-point ablation is not suitable.
Radiofrequency multi-electrode was not included as an alternative
due to its lower efficacy relative to cryoballoon and laser ablation
and concerns about a higher risk of stroke.
There was limited direct evidence for ablation in people with
persistent atrial fibrillation, but the committee decided that it was
sufficient to support radiofrequency point by point ablation (or
cryoballoonand laser ablation in the special circumstances outlined
above) as an option to be considered for those with persistent
symptoms that are unrelieved by antiarrhythmic drugs.
While evidence showed that ablation may reduce symptoms and
improve quality of life there was no evidence that it significantly
reduces serious clinical events suchas stroke, heart failure, or death.
Consequently, the decision to stop anticoagulation after ablation
should be based on stroke and bleeding risk assessed using
CHA2DS2-VASc and ORBIT as for all other patients with AF.
• If drug treatment is unsuccessful, unsuitable, or not tolerated in
people with symptomatic paroxysmal or persistent atrial
fibrillation:
‐ Consider radiofrequency point-by-point ablation or
‐ If radiofrequency point-by-point ablation is assessed as being
unsuitable, consider cryoballoon ablation or laser balloon
ablation.
[New guidance. Based on very low to low quality data]
• When considering left atrial ablation, discuss the risks and
benefits and take into account the person’s preferences. In
particular, explain that the procedure is not always effective and
that the resolution of symptoms may not be long lasting. [New
guidance. Based on very low to low quality data]
• Base decisions to stop anticoagulation on a reassessment of
stroke and bleeding risk using CHA2DS2-VASc and ORBIT and
a discussion of the person’s preferences. [New guidance. Based
on very low quality data]
Implementation
There are three main areas where implementation challenges exist.
Firstly, the use of the ORBIT score is a change in practice, which
may require some re-education in primary and secondary care, and
ORBIT will need to become embedded in GP systems. Secondly, the
recommendationsonanticoagulationare likely to lead toan increase
in use of direct-acting oral anticoagulants (DOACs), as part of an
ongoing trend. The unit cost of DOACs is greater than that for
warfarin, so there is likely to be a resource impact. Finally,
recommendations on ablation are likely to lead to a change in the
types of ablationoffered,withmorepeople receiving radiofrequency
point-by-point ablation and fewer having other catheter ablation
techniques.
Future research
During guideline development, evidence relating to new diagnostic
methods was not strong enough to permit new recommendations.
Alongside the research recommendations made in other areas, the
following research recommendations for diagnostic methods were made:
• What is the diagnostic accuracy of key index tests (such as the
KardiaMobile heart monitor (AliveCor), MyDiagnostik, Microlife BP
monitors, iPhone plethysmography, and pulse palpation) compared
with the gold standard of 12-lead electrocardiography in people with
risk factors for or symptoms of atrial fibrillation?
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• What is the diagnostic accuracy of key index tests compared with the
gold standard of prolonged ambulatory monitoring in people
suspected of having paroxysmal atrial fibrillation?
Guidelines into practice
• How can an accurate knowledge of a patient’s absolute risk of bleeding
be used to facilitate discussion about risk factor modification with a
patient who needs anticoagulation?
• How would you explain the potential benefits and harms of
radiofrequency ablation to a symptomatic patient who has not
responded to anti-arrhythmic drugs?
How patients were involved in the creation of this article
Committee members involved in this guideline update included lay
members who contributed to the formulation of the recommendations
summarised here.
Further information on the guidance
This guidance was developed by the National Guideline Centre in
accordance with NICE guideline methodology (www.nice.org.uk/media/de-
fault/about/what-we-do/our-programmes/developing-nice-guidelines-
the-manual.pdf). A guideline committee (GC) was established by the
National Guideline Centre, which incorporated healthcare and allied
healthcare professionals (one medical director for system improvement
and professional standards, two consultant cardiologists and
electrophysiologists, one cardiovascular research pharmacist and
principal pharmacist, one strategic lead for MSc Advanced Practice, one
GP principal, one chair of geriatrics and stroke medicine and consultant
in stroke medicine, one acute medicine, diabetes and clinical
pharmacology consultant, one clinical associate professor in primary
care and head of undergraduate primary care education, one arrythmia
nurse specialist, one chair in cardiovascular medicine and cardiology
consultant) and two lay members.
The GC identified relevant review questions and collected and appraised
clinical and cost effectiveness evidence. Quality ratings of the evidence
were based on GRADE methodology (www.gradeworkinggroup.org). These
relate to the quality of the available evidence for assessed outcomes or
themes rather than the quality of the study. The GC agreed
recommendations for clinical practice based on the available evidence
or, when evidence was not found or evidence was conflicting, based on
their experience and opinion using informal consensus methods.
The scope and the draft of the guideline went through a rigorous reviewing
process, in which stakeholder organisations were invited to comment;
the GC took comments into consideration when producing the final
version of the guideline.
The short version of the guideline, which includes the full list of
recommendations and their rationales and impacts, is available on the
NICE website in the Guidance section (https://www.nice.org.uk/guid-
ance/ng196). The evidence reviews, which provide the evidence
underpinning the recommendations and the GC discussion of the
evidence, are available in the Evidence section
(https://www.nice.org.uk/guidance/ng196/evidence).
NICE will conduct regular reviews after publication of the guidance to
determine whether the evidence base has progressed significantly enough
to alter the current guideline recommendations and require an update.
Contributors: All authors made substantial contributions to the conception or design or the work, as
well as the interpretation of data for thework. They all revised thework critically for important intellectual
content, approved the final version for publication, and agreed to be accountable for all aspects of the
work in ensuring that questions related to the accuracy or integrity of the work are investigated and
resolved. MPwrote the first draft, andMP, SKB, and NDmade substantial contributions to the acquisition
and interpretation of data for the work. MP is responsible for the overall content as guarantor.
Essential contributors included the NICE Guidelines Technical Support Unit (Department of Population
Health Sciences, Bristol Medical School), which helped produce the anticoagulation model; Dr Sharon
Swain, who directed the guideline; Dr Giulia Zuodar who managed the guideline; and Mrs Elizabeth
Pearton who carried out the literature searches. The guideline members contributed significantly to
the intellectual content of this guideline.
Funding: MP, SKB, and ND are employees of the National Guideline Centre, Royal College of Physicians,
which is commissioned and funded by NICE to develop clinical guidelines. SM received a small
honorarium from NICE for chairing the Guideline Committee. No authors received specific funding from
NICE to write this summary.
Competing interests: We have read and understood BMJ policy on declaration of interests and have
no relevant interests to declare.
Themembers of the Guideline Committee were (shown alphabetically): Neil Andrews, Matthew Bates,
Antony Chuter, Nazish Khan, Paulus Kirchhof, Geraldine Lee, SimonMackenzie, ThomasMcAnea, Irene
McGill, Chakravarthi Rajkumar, Yohan Samarasinghe, Jaspal Taggar, Keith Tyndall.
The guideline referred to in this article was produced by the National Guideline Centre for the National
Institute for Health and Care Excellence (NICE). The views expressed in this article are those of the
authors and not necessarily those of NICE.
1 National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management
(NICE guideline NG196). 2021. https://www.nice.org.uk/guidance/ng196.
2 National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and
management (NICE guideline NG136). 2019. https://www.nice.org.uk/guidance/ng136.
3 National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment
andmanagement of harmful drinking (high-risk drinking) and alcohol dependence (clinical guideline
CG115). 2011. https://www.nice.org.uk/guidance/cg115.
4 National Institute for Health and Care Excellence. Patient experience in adult NHS services:
improving the experience of care for people using adult NHS services (clinical guideline CG138).
2012. https://www.nice.org.uk/guidance/cg138.
5 National Institute for Health and Care Excellence. Medicines adherence: involving patients in
decisions about prescribedmedicines and supporting adherence (clinical guideline CG76). 2009.
https://www.nice.org.uk/guidance/cg76.
6 National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective
use of medicines to enable the best possible outcomes (NICE guideline NG5). 2015.
https://www.nice.org.uk/guidance/ng5.
7 Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs):
reminder of bleeding risk, including availability of reversal agents. https://www.gov.uk/drug-
safety-update/direct-acting-oral-anticoagulants-doacs-reminder-of-bleeding-risk-including-avail-
ability-of-reversal-agents.
8 National Institute for Health and Care Excellence. NICE Pathways: Atrial fibrillation overview.
https://pathways.nice.org.uk/pathways/atrial-fibrillation.
the bmj | BMJ 2021;373:n1150 | doi: 10.1136/bmj.n11504
PRACTICE
 on 16 A












J: first published as 10.1136/bm





Fig 1 | Algorithm for diagnosis and assessment of atrial fibrillation and prevention of stroke (excerpt from NICE guideline Atrial fibrillation: diagnosis and management1)
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Fig 2 | Algorithm for left atrial ablation strategies (excerpt from NICE guideline Atrial fibrillation: diagnosis and management1)
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